Psychedelic Business Spotlight: September 3, 2021
“Magic Truffle” producer and distributor Red Light Holland has had a very busy week, and Filament Health files a “milestone” patent.
Author: Emily Jarvie
DEA Proposes Huge Increase to Psilocybin and Psilocin Quotas for Research Purposes
In its proposed revised 2021 quotas, the DEA suggests 4900% increase in the allowed quantities of psilocybin for research and clinical trial purposes.
Psychedelic Sector Reaches International Supply Chain Milestones
Canadian psychedelics production company Red Light Holland announces largest legal sale and import of psilocybe truffles.
Mindset Pharma’s DMT-Inspired Drug Candidates Could Address Serotonin Syndrome Challenge
“The data suggests that we have a new drug that may be at least as effective, if not more effective, than 5-MeO-DMT and, more importantly, it looks like it is much safer,” says Mindset Pharma CEO James Lanthier.
Scientists Begin Exploring Therapeutic Potential of Psilocybin Mushrooms Native to Australia
“Australian native ‘magic mushrooms’ may have evolved different methods for psilocybin production and offer adaptations that are preferential for use in clinical treatments,” explains University of Queensland mycologist Dr. Alistair McTaggart.
California Bill Decriminalizing Psychedelics Delayed Until 2022
SB 519 would decriminalize the personal use of psilocybin, psilocyn, MDMA, LSD, DMT, mescaline (excluding peyote), and ibogaine, including in group counseling and community-based healing settings.
MindSet Pharma Says Its Psilocybin Formula Is the ‘Perfect Microdosing Drug’
“The potential market for microdosing could be absolutely enormous because it is easier, more convenient, and more familiar,” says Mindset Pharma CEO James Lanthier.
MindMed, Forian Developing Personalized Psychiatry for Anxiety Disorders
MindMed is currently conducting several clinical trials using psychedelic-inspired medicines, including studying LSD experiential therapy for anxiety, LSD microdosing for adult ADHD, and 18-MC for opioid withdrawal.
University of Wisconsin-Madison Launches New Psychedelic Research Center
This school offers the first accredited American degree focused on the study and therapeutic development of psychedelic compounds and related psychoactive drugs.
TRIPP Acquires PsyAssist to Empower Psychedelic Therapies with Virtual Reality
Clinicians are currently using TRIPP to help immerse patients into alternative realities and to support patients’ wellbeing before, during, and after ketamine-assisted therapy.
End of content
End of content